NodThera, a Cambridge, UK-based biotechnology company focused on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation, closed a £28m ($40m) Series A financing round.
The second closing of the round was co-led by healthcare investors Sofinnova Partners and 5AM Ventures, with further participation from Epidarex Capital and F-Prime Capital Partners. In conjunction wth the funding, Henrijette Richter, PhD, Managing Partner of Sofinnova Partners, and Scott Rocklage, PhD, Founding Partner of 5AM Ventures, will both join the Board of Directors with Henrijette Richter additionally serving as Chair.
Created and seed funded by life science investor Epidarex Capital in 2016 based on earlier research conducted at Selvita, a Polish drug discovery company which remains a shareholder in the company, NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.
Led by Alan Watt PhD MBA, Chief Scientific Officer and acting Chief Executive Officer, the company is developing small molecule inhibitors of the NLRP3 inflammasome, a multi-protein complex which initiates an innate immune response in the body. The NodThera strategy is to develop its drug candidate through to proof-of-concept in humans in an inflammatory disease and to bring forward further drug candidates specifically addressing high unmet medical needs such as neurodegenerative diseases and certain cancers.